Results from a NASEM report on social isolation & loneliness in older adults provides insight into challenges as a result of the COVID-19 pandemic.
The FDA has accepted for filing the supplemental New Drug Application (sNDA) for pimavanserin (Nuplazid®; Acadia) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
The majority of older US adults commonly experience ageism in their daily lives.
The researchers concluded that risk for MCI was associated with neurodegeneration and neuropsychiatric symptoms among adults aged 50 years and older, and that an abnormal FDG-PET was a stronger driving force for cognitive decline.
Elderly patients with hip fracture have an increased risk for suicide.
The majority of older adults in the sample did not report any depression, anxiety, or stress symptoms, and almost no respondents indicated severe or extremely severe symptoms.
Exposure to air pollution may have adverse effects on cognitive aging and brain health in older adults.
In older women, objectively measured visual impairment is associated with a twofold to more than fivefold increased risk for dementia.
Patients with psychiatric disorders are another population that may be more exposed to COVID-19, and the secondary effects of the pandemic may detract from ongoing treatment, thus worsening overall mental health.
Focused eating habits with high processed meats and unhealthy snacking may be associated with increased dementia risk.